MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
6883

688331.SS

RemeGen Co. Ltd. Class A

$112.99
-6.5
 (-5.44%)
Exchange:  SHH
Market Cap:  62.529B
Shares Outstanding:  487.444M
Delayed data
Calculate 688331.SS Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Pharmaceuticals
   
CEO:  Jian Min Fang
Full Time Employees:  3048
Address: 
58 Middle Beijing Road
Yantai
HN
411100
CN
Website:  http://www.remegen.com
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,082,953.4311,716,861.6873,249,588.961
Gross Profit825,6791,370,142.8292,618,286.542
EBITDA-1,312,022.986-1,164,974.7331,101,087.323
Operating Income-1,501,528.883-1,455,655.359130,195.351
Net Income-1,511,229.175-1,468,360.799709,649.797

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets5,528,2435,498,5197,248,072.288
Total Liabilities2,090,972.5383,512,3183,549,967.038
Total Stockholders Equity3,437,2691,986,2013,608,821.657
Total Debt1,259,9832,670,5112,201,708.515
Cash and Cash Equivalents709,073759,5301,197,548.786

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-1,501,829-1,176,59656,202.273
Capital Expenditure-852,756.843-264,568-200,006.323
Free Cash Flow-2,354,568-1,441,878-143,804.050
Net Income-1,511,229-1,468,362708,523.300
Net Change in Cash-1,342,62832,978435,056.391

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)8,309,348.308Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)12,688,350.623Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)10,672,000Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-5,317,532.933Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-3,482,346.492Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-4,472,504.989Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)0Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)5,668,586.810Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)8,655,915.521Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)7,280,373.406Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)13Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
18.49
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
49.56
?Enterprise Value
 (TTM)
: 
63.502B  ?EV/FCF
 (TTM)
: 
1311.77
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0.01
?ROE
 (TTM)
: 
0.42  ?ROIC
 (TTM)
: 
0.05
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.53
?P/B
 (TTM)
: 
16.09  ?Current Ratio
 (TTM)
: 
1.58

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
143.74Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about 688331.SS valuation

Is RemeGen Co. Ltd. Class A (688331.SS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for RemeGen Co. Ltd. Class A (688331.SS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is 688331.SS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 688331.SS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is 688331.SS’s P/E ratio?

You can see 688331.SS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for 688331.SS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is 688331.SS a good long-term investment?

Whether 688331.SS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

688331.SS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-5.44
MARKETSnap

Trading Metrics:

Open: 119.4   Previous Close: 119.49
Day Low: 112.87   Day High: 120.99
Year Low: 58.85   Year High: 156.79
Price Avg 50: 119.39   Price Avg 200: 106.14
Volume: 8.611M   Average Volume: 10.301M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read